Condition: Advanced Clear Cell Renal Cell Carcinoma · Metastatic Clear Cell Renal Cell Carcinoma · Stage III Renal Cell Cancer AJCC v8 · Sponsor: SWOG Cancer Research Network
This phase III trial compares the effect of adding live biotherapy, MO-03, to standard of care (SOC) immunotherapy, including ipilimumab, nivolumab, axitinib, pembrolizumab, cabozantinib, and lenvatinib, to SOC immunotherapy alone in treating patients with clear cell renal cell cancer that may have spread from where it first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started to other places in the body (metastatic). Studies have shown that gut health (the gut microbiome) may impact the effectiveness of immunotherapy. The microbiome includes all of the bacteria and organisms naturally found in the digestive tract. MO-03, a type of biotherapy, contains material from living organisms that may help keep the digestive tract healthy and may help to increase the effect of immunotherapy. Immunotherapy with monoclonal antibodies, such as ipilimumab, nivolumab, pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are a type of angiogenesis inhibitor and tyrosine kinase inhibitor (TKI) that block certain proteins which may help keep tumor cells from growing and may also help prevent the growth of new blood vessels that tumors need to grow. Adding MO-03 to SOC immunotherapy may be more effective than SOC immunotherapy alone in treating patients with advanced or metastatic clear …
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Highlands Oncology Group - Fayetteville | Fayetteville, Arkansas, United States | Recruiting |
| NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro | Jonesboro, Arkansas, United States | Recruiting |
| Highlands Oncology Group - Rogers | Rogers, Arkansas, United States | Recruiting |
| Highlands Oncology Group | Springdale, Arkansas, United States | Recruiting |
| Illinois CancerCare-Bloomington | Bloomington, Illinois, United States | Recruiting |
| Illinois CancerCare-Canton | Canton, Illinois, United States | Recruiting |
| Illinois CancerCare-Carthage | Carthage, Illinois, United States | Recruiting |
| Cancer Care Specialists of Illinois - Decatur | Decatur, Illinois, United States | Recruiting |
| Decatur Memorial Hospital | Decatur, Illinois, United States | Recruiting |
| Illinois CancerCare-Eureka | Eureka, Illinois, United States | Recruiting |
| Illinois CancerCare-Galesburg | Galesburg, Illinois, United States | Recruiting |
| Illinois CancerCare-Kewanee Clinic | Kewanee, Illinois, United States | Recruiting |
+ 29 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07383441